| Meshellia A Hayward, FNP | |
|
86 North Main Street, Greeleyville, SC 29056 | |
| (843) 426-2335 | |
| (843) 426-2346 |
| Full Name | Meshellia A Hayward |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 22 Years |
| Location | 86 North Main Street, Greeleyville, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750349353 | NPI | - | NPPES |
| NP1063 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 1814 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mcleod Health Clarendon | Manning, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hopehealth, Inc. | 4082510623 | 74 |
News Archive
Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).
In a study that enrolled nearly 30,000 apparently healthy men and women, those who had an increase in their resting heart rate over a 10-year period had an increased risk of death from all causes and from ischemic heart disease, according to a study in the December 21 issue of JAMA.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
A paper published today in the Proceedings of the National Academy of Sciences argues against the commonly held "accumulation of mutations" model of oncogenesis in favor of a model that depends on evolutionary pressures acting on populations of cells.
› Verified 4 days ago
| Entity Name | Hopehealth, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821002411 PECOS PAC ID: 4082510623 Enrollment ID: O20031212000253 |
News Archive
Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).
In a study that enrolled nearly 30,000 apparently healthy men and women, those who had an increase in their resting heart rate over a 10-year period had an increased risk of death from all causes and from ischemic heart disease, according to a study in the December 21 issue of JAMA.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
A paper published today in the Proceedings of the National Academy of Sciences argues against the commonly held "accumulation of mutations" model of oncogenesis in favor of a model that depends on evolutionary pressures acting on populations of cells.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meshellia A Hayward, FNP 360 N Irby St, Florence, SC 29501-2808 Ph: (843) 667-9414 | Meshellia A Hayward, FNP 86 North Main Street, Greeleyville, SC 29056 Ph: (843) 426-2335 |
News Archive
Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).
In a study that enrolled nearly 30,000 apparently healthy men and women, those who had an increase in their resting heart rate over a 10-year period had an increased risk of death from all causes and from ischemic heart disease, according to a study in the December 21 issue of JAMA.
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
A paper published today in the Proceedings of the National Academy of Sciences argues against the commonly held "accumulation of mutations" model of oncogenesis in favor of a model that depends on evolutionary pressures acting on populations of cells.
› Verified 4 days ago